Cargando…

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment

A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, Leonard B, Brook, Jill B, Myers, Trisha L, Goodman, Brent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778345/
https://www.ncbi.nlm.nih.gov/pubmed/29326369
http://dx.doi.org/10.1136/bcr-2017-221405
_version_ 1783294340146135040
author Weinstock, Leonard B
Brook, Jill B
Myers, Trisha L
Goodman, Brent
author_facet Weinstock, Leonard B
Brook, Jill B
Myers, Trisha L
Goodman, Brent
author_sort Weinstock, Leonard B
collection PubMed
description A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role.
format Online
Article
Text
id pubmed-5778345
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57783452018-01-29 Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment Weinstock, Leonard B Brook, Jill B Myers, Trisha L Goodman, Brent BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role. BMJ Publishing Group 2018-01-11 /pmc/articles/PMC5778345/ /pubmed/29326369 http://dx.doi.org/10.1136/bcr-2017-221405 Text en © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Weinstock, Leonard B
Brook, Jill B
Myers, Trisha L
Goodman, Brent
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title_full Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title_fullStr Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title_full_unstemmed Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title_short Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
title_sort successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
topic Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778345/
https://www.ncbi.nlm.nih.gov/pubmed/29326369
http://dx.doi.org/10.1136/bcr-2017-221405
work_keys_str_mv AT weinstockleonardb successfultreatmentofposturalorthostatictachycardiaandmastcellactivationsyndromesusingnaltrexoneimmunoglobulinandantibiotictreatment
AT brookjillb successfultreatmentofposturalorthostatictachycardiaandmastcellactivationsyndromesusingnaltrexoneimmunoglobulinandantibiotictreatment
AT myerstrishal successfultreatmentofposturalorthostatictachycardiaandmastcellactivationsyndromesusingnaltrexoneimmunoglobulinandantibiotictreatment
AT goodmanbrent successfultreatmentofposturalorthostatictachycardiaandmastcellactivationsyndromesusingnaltrexoneimmunoglobulinandantibiotictreatment